Patents by Inventor Michael SEBAG

Michael SEBAG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
    Patent number: 11279719
    Abstract: Novel C-2-substituted bicyclic compounds of Formula I have been prepared and found to be useful as inhibitors of by inhibiting geranylgeranylation of proteins. The application is directed to these compounds, to compositions comprising these compounds and to their use, in particular as medicaments to cancer and other conditions treatable by inhibiting human geranylgeranylation pyrophosphate hGGPPS activity.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: March 22, 2022
    Inventors: Youla S. Tsantrizos, Michael Sebag
  • SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20190367542
    Abstract: Novel C-2-substituted bicyclic compounds of Formula I have been prepared and found to be useful as inhibitors of by inhibiting geranylgeranylation of proteins. The application is directed to these compounds, to compositions comprising these compounds and to their use, in particular as medicaments to cancer and other conditions treatable by inhibiting human geranylgeranylation pyrophosphate hGGPPS activity.
    Type: Application
    Filed: July 12, 2019
    Publication date: December 5, 2019
    Inventors: Youla S. Tsantrizos, Michael Sebag
  • THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND/OR GERANYLGERANYL PYROPHOSPHATE SYNTHASE
    Publication number: 20150307532
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;
    Type: Application
    Filed: November 19, 2013
    Publication date: October 29, 2015
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Youla S. TSANTRIZOS, Judes POIRIER, Michael SEBAG, Albert BERGHUIS, Jaeok PARK, Joris WIM DE SCHUTTER
  • Method of obtaining circulating cancer cell populations
    Patent number: 9057055
    Abstract: It is herewith provided methods of obtaining circulating cancer cells (CCCs)-enriched cellular populations based on the removal of CD45-positive cells from an apheresis product. It is also provided methods of obtaining circulating stem cells (CSCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection either using the specific cellular markers or through culture. It is further provided methods of obtaining circulating tumor cells (CTCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection using the specific cellular markers. It is also provided screening assays for the selection of (chemo)therapeutic agent as well as personalized medicine application based on drug sensitivity/resistance or cancer markers.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: June 16, 2015
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Catalin Mihalcioiu, Richard Kremer, Michael Sebag, Ramy Saleh, Jiarong Li
  • METHOD OF OBTAINING CIRCULATING CANCER CELL POPULATIONS, ASSOCIATED CELLULAR COMPOSITIONS AND METHODS OF USING SAME
    Publication number: 20140154799
    Abstract: It is herewith provided methods of obtaining circulating cancer cells (CCCs)-enriched cellular populations based on the removal of CD45-positive cells from an apheresis product. It is also provided methods of obtaining circulating stem cells (CSCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection either using the specific cellular markers or through culture. It is further provided methods of obtaining circulating tumor cells (CTCs)-enriched cellular population from a CCCs-enriched cellular population based on a selection using the specific cellular markers. It is also provided screening assays for the selection of (chemo)therapeutic agent as well as personalized medicine application based on drug sensitivity/resistance or cancer markers.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 5, 2014
    Inventors: Catalin MIHALCIOIU, Richard KREMER, Michael SEBAG, Ramy SALEH, Jiarong LI